Crocins are water-soluble plant pigments in saffron and gardenia fruit used as a dietary supplement to counter cellular stress and inflammation. Oral administration of 15 to 30 milligrams daily relieves nerve pain and tingling, reduces depressive and anxiety symptoms, and modestly lowers blood sugar, with single-group evidence for eye, heart, and lung protection but negligible cholesterol effects. Four-to-twelve-week use is well tolerated with laboratory monitoring. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting Blood Glucose (FBG) | 70–99 mg/dL (standard reference range) | Efficacy marker: tracks glycemic reduction and checks for additive hypoglycemia. |
| Hemoglobin A1c (HbA1c) | <5.7% (standard reference range) | Efficacy marker: evaluates 8–12 week improvement in average glycemic exposure. |
| High-Sensitivity C-Reactive Protein (hs-CRP) | <3.0 mg/L (standard reference range) | Efficacy marker: quantifies systemic anti-inflammatory response to crocin. |
| Serum Creatinine and eGFR | Creatinine 0.6–1.2 mg/dL; eGFR >60 mL/min/1.73 m² (standard reference range) | Safety check: detects subclinical creatinine elevation (protocols discontinue if creatinine >2.0 mg/dL or eGFR <30 mL/min/1.73 m²). |
| Complete Blood Count (CBC) with Differential | White blood cells 4,500–11,000 cells/μL (standard reference range) | Safety check: screens for leukopenia, especially during concurrent chemotherapy. |
| Central Macular Thickness (via OCT) | No established target; reduction from individual baseline | Efficacy marker: quantifies resolution of macular thickening in retinal protocols. |
Cadence: Baseline laboratory testing (plus seated blood pressure and baseline OCT when targeting macular health); 4 weeks for CBC and blood pressure checks in medicated or chemotherapy-treated individuals; 8 to 12 weeks for metabolic (FBG, HbA1c), inflammatory (hs-CRP), ocular (OCT), and renal (creatinine, eGFR) reassessment, and every 6 months during extended protocols.